Hyperviscosity Syndrome
Elevated serum viscosity from excess immunoglobulins (Waldenström IgM most common) or extreme leukocytosis/polycythemia. Classic triad: bleeding, visual changes, neurologic symptoms. Emergent plasmapheresis.
🔍 Overview
Causes
| Cause | Details |
|---|---|
| Waldenström macroglobulinemia | #1 cause. IgM paraprotein -large pentamer is most viscous. Symptoms at IgM > 3 g/dL. |
| Multiple myeloma | Less common (IgA > IgG -IgA polymerizes). ~2–5% of MM cases. |
| Leukostasis | WBC > 100K (AML) or > 200–300K (CLL/ALL). White cell plugging in microvasculature. |
| Polycythemia vera | Hct > 60–65%. RBC sludging. |
Classic Triad
- Mucosal bleeding -epistaxis, gingival bleeding (paraprotein interferes with platelet function and clotting factors)
- Visual changes -blurred vision, "sausage-link" retinal veins on fundoscopy, retinal hemorrhages
- Neurologic symptoms -headache, confusion, dizziness, stroke, coma
Do NOT transfuse pRBCs before plasmapheresis in paraprotein hyperviscosity -adding RBCs to already viscous blood will worsen sludging and can precipitate stroke or MI.
Pathophysiology
Excess paraprotein (most commonly IgM) increases serum viscosity, leading to sludging of blood in the microvasculature. This causes hypoperfusion and end-organ damage affecting the brain, eyes, and mucosal surfaces. IgM is the most common cause because it exists as a pentamer (~900 kDa) -five immunoglobulin subunits linked together -making it far larger than IgG (~150 kDa) or IgA (~160 kDa monomer). Even modest concentrations of IgM dramatically increase viscosity. IgA can also cause hyperviscosity because it tends to polymerize, but this is less common. IgG rarely causes hyperviscosity because it remains a small monomer. The relationship between immunoglobulin concentration and viscosity is exponential, not linear -small increases in paraprotein at high levels cause disproportionate rises in viscosity. Additionally, paraproteins interfere with platelet aggregation and clotting factor function, contributing to the bleeding diathesis.
Clinical Triad -Detailed Findings
| Category | Specific Findings | Mechanism |
|---|---|---|
| Mucosal Bleeding | Epistaxis (most common), gingival bleeding, GI bleeding, menorrhagia, purpura | Paraprotein coats platelets (impaired aggregation) and interferes with fibrin polymerization and clotting factors |
| Visual Changes | Blurred vision, diplopia, visual loss. Fundoscopy: "sausage-link" retinal veins (alternating dilated/constricted segments), Roth spots, retinal hemorrhages (flame-shaped), papilledema, cotton-wool spots | Hyperviscous blood distends retinal veins and causes stasis → retinal ischemia and hemorrhage |
| Neurologic Symptoms | Headache, dizziness, vertigo, confusion, somnolence, obtundation, hearing loss, ataxia, stroke, coma | Cerebral hypoperfusion from sludging in cerebral microvasculature; can progress to frank infarction |
Diagnostic Workup
| Test | Expected Finding | Significance |
|---|---|---|
| Serum viscosity | Normal: 1.4–1.8 cP. Symptomatic: > 4 cP. Emergency: > 5–6 cP | Definitive measurement. Must be ordered specifically (not part of routine labs). |
| SPEP / Immunofixation | M-spike on electrophoresis; immunofixation identifies isotype (IgM, IgA, IgG) | Identifies the paraprotein. Large M-spike correlates with viscosity. |
| UPEP (24-hr urine) | Bence Jones protein (free light chains) | Supports myeloma diagnosis; assesses renal light-chain burden. |
| Quantitative immunoglobulins | Markedly elevated IgM (> 3 g/dL) in Waldenström; elevated IgA or IgG in myeloma | IgM > 3 g/dL almost always causes symptoms. Other Ig levels may be suppressed. |
| Fundoscopic exam | "Sausage-link" retinal veins, Roth spots, flame hemorrhages, papilledema | Pathognomonic findings. Should be performed on ALL suspected cases. Findings resolve after plasmapheresis. |
| CBC with peripheral smear | Rouleaux formation (RBCs stacked like coins), anemia, possible leukocytosis | Rouleaux is classic. Anemia may be dilutional or from marrow infiltration. |
| Coagulation studies | Prolonged PT/PTT, prolonged thrombin time | Paraprotein interferes with clotting factors and fibrin polymerization. |
| BMP, LDH, uric acid | Elevated LDH, elevated uric acid, possible renal insufficiency | Assess for tumor lysis risk and end-organ damage. |
Mnemonic -VISCOUS (Hyperviscosity Syndrome):
Vision changes (blurred vision, "sausage-link" veins, Roth spots) · Immunoglobulin (IgM most common -pentamer) · Sludging of blood (hypoperfusion, microvasculature) · Coagulopathy / bleeding (epistaxis, mucosal, platelet dysfunction) · Obtundation / neuro symptoms (headache, confusion, coma) · Underlying cause (Waldenström #1, myeloma, leukostasis) · Serum viscosity > 4 cP (emergency > 5–6 cP)
Vision changes (blurred vision, "sausage-link" veins, Roth spots) · Immunoglobulin (IgM most common -pentamer) · Sludging of blood (hypoperfusion, microvasculature) · Coagulopathy / bleeding (epistaxis, mucosal, platelet dysfunction) · Obtundation / neuro symptoms (headache, confusion, coma) · Underlying cause (Waldenström #1, myeloma, leukostasis) · Serum viscosity > 4 cP (emergency > 5–6 cP)
Clinical Examples
📋 Case 1, Waldenström with Epistaxis and Visual Changes
Patient: 68M with known Waldenström macroglobulinemia presents with recurrent epistaxis and blurred vision over the past 3 days. On exam, bilateral retinal hemorrhages and "sausage-link" retinal veins on fundoscopy.
Labs: Serum viscosity 8.2 cP (markedly elevated). IgM 5.8 g/dL. CBC shows rouleaux formation. Hgb 9.2.
Action:
- Emergent plasmapheresis -viscosity 8.2 is critically elevated. Do NOT wait for heme/onc consult to initiate.
- Aggressive IV NS -hydration to reduce viscosity while awaiting pheresis.
- Do NOT transfuse pRBCs -will worsen sludging at this viscosity level.
- Serial fundoscopic exams after pheresis to confirm resolution of retinal findings.
- After viscosity controlled, discuss initiation of rituximab-based chemotherapy with heme/onc.
📋 Case 2, Multiple Myeloma (IgA) with Confusion
Patient: 72F with IgA multiple myeloma on lenalidomide presents with progressive confusion and severe headache over 24 hours. Family reports increasing somnolence.
Labs: Serum viscosity 5.1 cP. IgA 6.2 g/dL (polymerized). BMP shows Cr 2.1 (baseline 1.0). Peripheral smear shows rouleaux.
Action:
- Plasmapheresis -symptomatic hyperviscosity with neurologic findings. IgA less commonly causes hyperviscosity than IgM, but this patient's IgA is polymerizing.
- Neuro checks q1h -monitor for progression to obtundation or coma.
- CT head -rule out intracranial hemorrhage or stroke as alternative/concurrent diagnosis.
- Discuss chemotherapy adjustment with heme/onc -current regimen not controlling disease.
- Monitor renal function -Cr elevation may be from hyperviscosity-related renal hypoperfusion or light-chain nephropathy.
📋 Case 3, New Waldenström with DVT and Hyperviscosity
Patient: 55M presents with left leg DVT and is incidentally found to have IgM 4.5 g/dL on workup. Reports fatigue and "haziness" in vision for weeks. Fundoscopy shows early sausage-link changes. Serum viscosity 4.8 cP.
Action:
- New diagnosis of Waldenström macroglobulinemia with symptomatic hyperviscosity. Bone marrow biopsy for confirmation.
- Plasmapheresis -symptomatic with visual changes and viscosity 4.8 cP.
- Anticoagulation for DVT -heparin drip (monitor closely given bleeding risk from paraprotein).
- Avoid pRBC transfusion before viscosity is reduced -even if Hgb is low, transfusion can precipitate stroke/MI.
- Rituximab-based therapy (e.g., bendamustine-rituximab or ibrutinib) for definitive treatment. Note: rituximab can cause transient "IgM flare" (paradoxical IgM rise) -pheresis may need to be repeated.
🚨 Management
Emergent Treatment
- Plasmapheresis (plasma exchange) -first-line for symptomatic hyperviscosity. Removes paraprotein directly. 1–2 sessions typically provide rapid relief.
- Leukostasis: Leukapheresis + hydroxyurea + start definitive chemotherapy. IV fluids for dilution.
- Polycythemia: Phlebotomy to target Hct < 45%.
- IV fluids -aggressive hydration to reduce viscosity
- Avoid diuretics -worsens hemoconcentration
- Avoid pRBC transfusion -until viscosity is reduced (except for life-threatening anemia)
🧪 Workup
- Serum viscosity -normal 1.4–1.8 cP. Symptoms typically at > 4 cP. Emergency at > 5–6 cP.
- SPEP + immunofixation -identify paraprotein
- CBC with diff -WBC count (leukostasis), Hct (polycythemia)
- Quantitative immunoglobulins
- Fundoscopic exam -"sausage-link" veins, papilledema, retinal hemorrhages
- BMP, LDH, uric acid
- Coagulation studies -may be abnormal (paraprotein interference)
💊 Medications
| Intervention | Details | Notes |
|---|---|---|
| Plasmapheresis | 1–1.5 plasma volumes per session | First-line. 1–2 sessions for symptom relief. Bridge to chemotherapy. |
| IV NS | Aggressive hydration | Dilute viscous blood. Avoid dehydration. |
| Hydroxyurea (Hydrea) | 50–100 mg/kg/day | Leukostasis -cytoreduction while awaiting chemo |
| Phlebotomy | Target Hct < 45% | Polycythemia vera |
📋 On Rounds
Pimp Questions
Why is IgM the most common cause of hyperviscosity among paraproteins?
IgM exists as a pentamer -5 immunoglobulin units linked together, making it the largest antibody (~900 kDa vs 150 kDa for IgG). This enormous size dramatically increases serum viscosity even at relatively modest concentrations. IgA can also cause hyperviscosity because it polymerizes, but IgG rarely does. This is why Waldenström (IgM-producing) causes hyperviscosity much more commonly than myeloma (usually IgG).
What is the difference between hyperviscosity from paraproteins vs leukostasis?
Paraprotein hyperviscosity: Increased serum viscosity from immunoglobulin. Treated with plasmapheresis. Leukostasis: NOT truly viscosity -it's mechanical plugging of microvasculature by large, sticky blast cells (AML blasts are stickier than ALL). WBC > 100K in AML is concerning. Treated with leukapheresis + hydroxyurea + emergent chemo. Both present similarly (CNS, pulmonary, bleeding), but treatment is different.
Why should you avoid RBC transfusion before plasmapheresis in hyperviscosity?
In paraprotein-mediated hyperviscosity, the serum is already abnormally viscous from excess immunoglobulin. Transfusing packed RBCs increases the cellular fraction of blood (raises hematocrit) without removing any paraprotein, causing a dramatic further rise in whole-blood viscosity.
Why is IgM the most common immunoglobulin causing hyperviscosity?
IgM circulates as a pentamer -five immunoglobulin subunits linked together by J chains and disulfide bonds, creating a massive molecule of approximately 900 kDa. Compare this to IgG at ~150 kDa (monomer) or IgA at ~160 kDa (monomer, though it can dimerize to ~320 kDa). The enormous hydrodynamic radius of the IgM pentamer means it dramatically increases the viscosity of plasma even at relatively low concentrations.
⚡ Summary
The Triad
Mucosal bleeding, visual changes and neurologic symptoms. Epistaxis is the commonest bleed; the visual complaint ranges from blurring to sudden loss; the neurology runs from headache and vertigo to confusion, seizure and coma. Any two of the three in a patient with a paraprotein or an extreme cell count is the diagnosis until disproven.
Know Which Diseases Cause It
Waldenstrom macroglobulinemia is number one, because IgM is a pentamer and is by far the most viscous molecule. Multiple myeloma is less common, about 2 to 5% of cases, and then usually IgA (which polymerizes) rather than IgG. Leukostasis with WBC above 100,000 in AML or above 200,000 to 300,000 in lymphoid leukemias. Polycythemia vera with a hematocrit above 60 to 65%.
Look at the Fundus
Dilated, segmented retinal veins, the 'sausage-link' or 'boxcar' appearance, with hemorrhages, exudates and papilledema. This is the fastest bedside confirmation available and it can be done before any laboratory result returns.
Confirm and Quantify
Serum viscosity, normal 1.4 to 1.8 centipoise; symptoms usually appear above 4 to 5. Send serum protein electrophoresis with immunofixation and free light chains, a CBC with differential and a smear (look for rouleaux), and a type and screen. Treat on the clinical picture rather than waiting for the viscosity result, which is often a send-out.
Plasmapheresis Is the Emergency Treatment
It removes the paraprotein directly and symptoms improve within hours. It works best for IgM, which is largely intravascular, so a single session removes most of it. It is a temporizing measure only: without treating the underlying clone, viscosity returns within days.
The Transfusion Trap
Do not transfuse red cells before plasmapheresis in paraprotein hyperviscosity. Adding red cells to already sludging blood raises viscosity further and can precipitate stroke or myocardial infarction. The anemia is largely dilutional, so the measured hemoglobin overstates the problem. If transfusion is unavoidable, give it during or after apheresis.
Match the Procedure to the Cell Line
Paraprotein → plasmapheresis. Leukostasis → leukapheresis plus urgent cytoreduction with hydroxyurea or induction chemotherapy. Polycythemia → therapeutic phlebotomy. Plasmapheresis does nothing for a cellular cause, and confusing the two loses hours the patient does not have.
Then Treat the Disease Underneath
Rituximab-based therapy for Waldenstrom, but be aware of the IgM flare: rituximab transiently raises IgM and can worsen viscosity, so plasmapherese first and consider deferring rituximab in the first cycle. Anti-myeloma therapy for myeloma, cytoreduction for leukostasis with tumor lysis prophylaxis, and cytoreductive therapy plus aspirin for polycythemia vera.
📄 One Pager
Text version
HEME / ONC · One Pager
Hyperviscosity Syndrome
An emergency. Bleeding, blurred vision, and confusion in a patient with a paraprotein means the blood is too thick to perfuse the brain and retina. Plasmapheresis is the definitive move, and pRBCs before pheresis can kill.
The Classic Triad
- Mucosal bleeding: epistaxis (most common), gingival bleeding, GI bleeding, menorrhagia, purpura. The paraprotein coats platelets (impaired aggregation) and interferes with fibrin polymerization and clotting factors, so PT/PTT and thrombin time can be prolonged with no primary coagulopathy.
- Visual changes: blurred vision, diplopia, visual loss. Fundoscopy shows "sausage-link" retinal veins (alternating dilated and constricted segments), Roth spots, flame-shaped retinal hemorrhages, papilledema, cotton-wool spots. Hyperviscous blood distends the retinal veins and causes stasis, leading to retinal ischemia and hemorrhage.
- Neurologic symptoms: headache, dizziness, vertigo, confusion, somnolence, obtundation, hearing loss, ataxia, stroke, coma. Cerebral microvascular sludging causes hypoperfusion that can progress to frank infarction, which is why this is time-sensitive.
- Do the fundoscopic exam on every suspected case. The findings are pathognomonic, they are available at the bedside before the viscosity result comes back, and they resolve after plasmapheresis so they also serve as your response marker.
Causes, Most Common First
- Waldenström macroglobulinemia, the #1 cause. IgM paraprotein; the large pentamer is the most viscous immunoglobulin. Symptoms appear at IgM > 3 g/dL.
- Multiple myeloma, less common, about 2–5% of MM cases. IgA > IgG because IgA polymerizes; IgG rarely does this because it stays a small monomer.
- Leukostasis: WBC > 100K in AML, or > 200–300K in CLL/ALL. This is not true viscosity, it is mechanical plugging of the microvasculature by large sticky blast cells (AML blasts are stickier than ALL), and that is why the treatment differs.
- Polycythemia vera: Hct > 60–65% with RBC sludging.
- Why IgM dominates: IgM circulates as a pentamer (~900 kDa) versus IgG at ~150 kDa and IgA at ~160 kDa as a monomer. The relationship between immunoglobulin concentration and viscosity is exponential, not linear, so small increases at high levels cause disproportionate rises in viscosity.
Management, Step by Step
1
Recognize at the bedside: triad symptoms plus fundoscopy. Do not wait for the viscosity level to act if the retina and the neuro exam already tell you.
2
Send serum viscosity: normal 1.4–1.8 cP, symptomatic typically > 4 cP, emergency > 5–6 cP. It must be ordered specifically, it is not part of routine labs, so it will not appear unless you ask for it.
3
Emergent plasmapheresis (plasma exchange), 1–1.5 plasma volumes per session. First-line for symptomatic paraprotein hyperviscosity because it removes the paraprotein directly; 1–2 sessions typically give rapid relief. Do not wait for the heme/onc consult to initiate.
4
Aggressive IV normal saline to dilute viscous blood while awaiting pheresis. Avoid diuretics, they worsen hemoconcentration and make the viscosity worse.
5
Treat by mechanism, not by label: leukostasis gets leukapheresis + hydroxyurea + emergent chemotherapy plus IV fluids, since pheresis of plasma does nothing for cell plugging. Polycythemia gets phlebotomy to a target Hct < 45%.
6
Bridge to definitive therapy. Plasmapheresis buys time, it does not treat the clone. Once viscosity is controlled, start rituximab-based therapy for Waldenström or adjust the myeloma regimen with heme/onc.
Key Interventions
Plasmapheresis1–1.5 plasma volumes per session; first-line, 1–2 sessions for symptom relief, bridge to chemotherapy
IV normal salineaggressive hydration to dilute viscous blood; avoid dehydration and avoid diuretics
Leukapheresisfor leukostasis, removes the plugging blasts that plasma exchange cannot touch
Hydroxyurea (Hydrea)50–100 mg/kg/day; cytoreduction in leukostasis while awaiting definitive chemotherapy
Phlebotomytarget Hct < 45% in polycythemia vera
Rituximab-based therapydefinitive treatment for Waldenström after viscosity is controlled; can cause a transient "IgM flare"
Workup and Numbers
- Serum viscosity: normal 1.4–1.8 cP, symptoms > 4 cP, emergency > 5–6 cP. The definitive measurement, and it must be ordered specifically.
- SPEP with immunofixation: M-spike plus isotype (IgM, IgA, IgG). A large M-spike correlates with viscosity.
- Quantitative immunoglobulins: IgM > 3 g/dL almost always causes symptoms in Waldenström; other Ig levels may be suppressed.
- UPEP (24-hr urine): Bence Jones protein, supports myeloma and gauges renal light-chain burden.
- CBC with peripheral smear: rouleaux formation (RBCs stacked like coins) is classic. Anemia may be dilutional or from marrow infiltration.
- Coagulation studies: prolonged PT/PTT and thrombin time from paraprotein interference, not from factor deficiency.
- BMP, LDH, uric acid: assess tumor lysis risk and end-organ damage.
- Serial fundoscopy after pheresis to confirm the retinal findings are resolving, which is your objective evidence the viscosity actually came down.
Pitfalls
- Transfusing pRBCs before plasmapheresis. This is the classic killer. Adding RBCs raises the cellular fraction without removing any paraprotein, causing a dramatic further rise in whole-blood viscosity, which worsens sludging and can precipitate stroke or MI. Hold transfusion until viscosity is reduced, even if the Hgb looks low.
- Giving diuretics for the "volume overloaded" appearance. They worsen hemoconcentration and drive viscosity up.
- Not ordering serum viscosity, then concluding the labs are unremarkable. It is not on any routine panel.
- Treating leukostasis with plasmapheresis. Leukostasis is cell plugging, not plasma viscosity; it needs leukapheresis, hydroxyurea, and emergent chemotherapy. Both syndromes look alike (CNS, pulmonary, bleeding) but the therapy differs.
- Forgetting the rituximab "IgM flare." Rituximab can cause a paradoxical transient rise in IgM in Waldenström, so pheresis may need to be repeated.
- Assuming a normal PT/PTT excludes bleeding risk, or assuming an abnormal one means DIC. The paraprotein itself interferes with platelet function and fibrin polymerization.
Escalate / Act Immediately When
- Serum viscosity > 5–6 cP: emergency range, initiate plasmapheresis without waiting.
- Any neurologic finding (confusion, somnolence, focal deficit): pheresis plus neuro checks q1h to catch progression to obtundation or coma, and CT head to rule out intracranial hemorrhage or stroke as an alternative or concurrent diagnosis.
- Sausage-link retinal veins or new visual loss: retinal ischemia is already happening, treat as emergent.
- Rising creatinine: may reflect hyperviscosity-related renal hypoperfusion or light-chain nephropathy; both change urgency and both need heme/onc input.
- New paraprotein without a known diagnosis: bone marrow biopsy for confirmation once the patient is stabilized, not before pheresis.
- Concurrent thrombosis: anticoagulate but monitor closely, because the same paraprotein that causes clotting risk also causes a bleeding diathesis.
VISCOUS Mnemonic
- Vision changes (blurred vision, sausage-link veins, Roth spots)
- Immunoglobulin (IgM most common, the pentamer)
- Sludging of blood (hypoperfusion in the microvasculature)
- Coagulopathy and bleeding (epistaxis, mucosal, platelet dysfunction)
- Obtundation and neuro symptoms (headache, confusion, coma)
- Underlying cause (Waldenström #1, myeloma, leukostasis)
- Serum viscosity > 4 cP (emergency > 5–6 cP)
Related Topics
Acute Leukemia (AML / ALL)AmyloidosisAnemia WorkupAnemia WorkupAnticoagulation ManagementChemotherapy Toxicities